SCHEMBL5533149

SCHEMBL5533149

Cc1cc(N)c(C(=O)O)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD44 P16070 1/20 0.56
KDM4E B2RXH2 4/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP3A4 P08684 1/20 0.46
IDO1 P14902 1/20 0.46
ALDH1A1 P00352 4/20 0.44
POLB P06746 3/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GFER P55789 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6584037 0.92 CD44 (0.56) CD44KDM4EKMT2AMEN1TDP1
SCHEMBL31255799 0.84 CD44 (0.56) CD44KDM4EKMT2AMEN1TDP1
SCHEMBL10915062 0.84 POLB (0.47) CD44KDM4EKMT2AMEN1TDP1
SCHEMBL30079667 0.83 KDM4E (0.52) KDM4EKMT2AMEN1TDP1CYP3A4
SCHEMBL4628056 0.83 SORT1 (0.46) KDM4EKMT2AMEN1TDP1ALDH1A1
SCHEMBL3031603 0.83 CYP3A4 (0.52) KDM4EKMT2AMEN1TDP1CYP3A4
SCHEMBL974647 0.83 KDM4E (0.52) KDM4EKMT2AMEN1TDP1CYP3A4
SCHEMBL18669166 0.81 SLC9A1 (0.58) KDM4EKMT2AMEN1TDP1CYP3A4
SCHEMBL31277421 0.81 ALDH1A1 (0.51) KDM4EKMT2AMEN1TDP1CYP3A4
SCHEMBL29087117 0.81 SORT1 (0.45) KDM4EKMT2AMEN1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 US disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
EP-2842946-B1 QUINAZOLINEDIONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-09-28 EP disclosed
CN-100537222-C Solvent stable tinted iridescent film ENGELHARD CORP (US) 2009-09-09 CN disclosed
US-20070269641-A1 Solvent Stable Tinted Iridescent Film GRANEY DANIEL J 2007-11-22 US disclosed
CN-1839038-A Solvent stable tinted iridescent film ENGELHARD CORP (US) 2006-09-27 CN disclosed
EP-1656252-A1 SOLVENT STABLE TINTED IRIDESCENT FILM Engelhard Corporation (US) 2006-05-17 EP disclosed
WO-2005018931-A1 SOLVENT STABLE TINTED IRIDESCENT FILM ENGELHARD CORPORATION (US) 2005-03-03 WO disclosed
WO-2003106435-A1 FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF SANKYO COMPANY, LIMITED (JP) 2003-12-24 WO disclosed
EP-0914386-B1 PIGMENT COMPOSITIONS ENGELHARD CORP (US) 2002-03-27 EP disclosed
US-5669967-A MONOAZO DYES, PYRAZOLE DYES FOR INKS, PAINTS AND PLASTICS ENGELHARD CORPORATION (US) 1997-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT CD44 2947/4885KDM4E 2544/4885KMT2A 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.